CI

At a glance

ClinicalIndex Comparison Record
Phase 4Active· 68 target
Drug / intervention
Nepafenac and lubricant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07372014
NCT07372014Phase 4ActiveMonitorUpdated 5mo ago · Completion was 4mo ago
Slow Enrollment

A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum Stenosis in Mexican Adults

Instituto de Oftalmología Fundación Conde de Valenciana·interventional·Posted Jan 28, 2026·Updated Jan 28, 2026

In Brief

A Phase 4 clinical trial evaluating Nepafenac and lubricant and Placebo for Epiphora and Punctal Stenosis. Active but no longer recruiting, targeting 68 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

Establish the efficacy of combined treatment with nepafenac and lubricant versus lubricant alone in improving epiphora and resolving punctal stenosis in Mexican adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico
Collaborators--

Timeline

Phase 4ActiveOverdue
2026
First PostedJan 28, 2026
Enrollment StartJan 12, 2026
Primary CompletionMar 2, 2026
Study CompletionMay 29, 2026
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5 months ago

Interventions

Nepafenac and lubricantdrug

A two-month follow-up will be conducted. The study participants will be randomly assigned to two groups: the first group will receive treatment with nepafenac 0.1% ophthalmic suspension once daily and sodium carboxymethylcellulose 0.5% (lubricant) three times daily for eight weeks; the second group will receive treatment with placebo and lubricant only, administered three times daily for eight weeks

Placebodrug

A two-month follow-up will be conducted. The study participants will be randomly assigned to two groups: the first group will receive treatment with nepafenac 0.1% ophthalmic suspension once daily and sodium carboxymethylcellulose 0.5% (lubricant) three times daily for eight weeks; the second group will receive treatment with placebo and lubricant only, administered three times daily for eight weeks